Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San ...
EarlyDiagnostics, Inc. ("EarlyDx"), a clinical-stage liquid biopsy company developing precision diagnostics, today announced that its proprietary MethylScantm platform has been validated in a ...
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial A substantial proportion of cancers are ...
Tranexamic acid significantly enhances hemostasis, achieving success rates between 83.1% and 95.0% when applied both ...
Syncromune is advancing SYNC-T Therapy SV-102 in the ongoing Phase 2 LEGION-100 study (NCT06533644), which is actively enrolling across multiple sites in the U.S. Please visit www.legion100trial.com ...
Hosted on MSN
Master patient assessment like a pro paramedic
Why structure matters: Frameworks like ABCDE standardize patient assessment, helping responders act quickly and consistently under pressure. From scene to bedside ...
EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...
A new research paper was published in Volume 18 of Aging-US on April 24, 2026, titled “The BHARAT study: a multi-modal, multi ...
Prophylactic administration of obinutuzumab, a B-cell-depleting antibody, reduces the incidence of corticosteroid-requiring chronic graft-vs-host disease (cGVHD) at 1 year from 35.2% to 13.3% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results